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The cellular protein Cyclophilin A (Cyp A) is packaged into human immunodeficiency virus type 1 (HIV-1) particles through
a specific interaction with the capsid domain of the Gag polyprotein. Inhibition of Cyp A incorporation by mutagenesis or
cyclosporin treatment severely affects infectivity of all HIV-1 M subtypes tested. In contrast, the closely related lentiviruses
HIV-2 and simian immunodeficiency virus (SIV) do not package Cyp A and are not inhibited by cyclosporin. For the HIV-1
group O isolate MVP5180, it was found that Cyp A incorporation and Cyp A dependence of infectivity did not correlate. This
virus incorporates Cyp A but is not sensitive to treatment with cyclosporin A. For a more detailed study concerning the
relationship between Cyp A incorporation and Cyp A dependence, we have analyzed five group O isolates for their ability to
incorporate Cyp A and their sensitivity to cyclosporin treatment. All group O viruses incorporated Cyp A in comparable
amounts as the M-group HIV-1 strain NL4-3. Furthermore, Cyp A incorporation was inhibited by cyclosporin in all cases.
However, while isolate MVP 5180 was confirmed to replicate independent of Cyp A, three of the other four isolates were
sensitive to cyclosporin treatment. Sequence analysis of the Cyp A binding regions revealed that the proline-rich motif, which
is responsible for Cyp A incorporation, was conserved in all four isolates, while some sequence variations were detected in
other positions close to this region. These results suggest that Cyp A dependence of replication is influenced by regionsof Cyp
groupINTRODUCTION
The human immunodeficiency virus type 1 (HIV-1) Gag
polyprotein is sufficient for the assembly and release of
enveloped particles in the absence of other viral pro-
teins. The accumulation of Gag polyproteins at the
plasma membrane leads to the assembly of immature
virions that bud from the cell surface (Craven et al., 1996;
Gheysen et al., 1989; Shields et al., 1978; Wills and
Craven, 1991). These noninfectious particles contain a
spherical shell closely apposed to the viral membrane
(Fuller et al., 1997; Gelderblom, 1991; O¨hagen et al.,
1997). Within the budding virion, the polyproteins are
cleaved by the viral proteinase (PR) into matrix (MA),
capsid (CA), and nucleocapsid (NC) proteins and some
smaller peptides (Kra¨usslich and Wimmer, 1988; Kuo and
Shafer, 1994). These cleavages lead to a major change of
the internal virion structure termed maturation. Matura-
tion corresponds to the condensation of the cone-
shaped capsid encasing an internal ribonucleoprotein
complex consisting of the viral RNA genome bound to
NC and other viral replication proteins (Gelderblom,
1991; Wills and Craven, 1991). Although Gag alone is
1 To whom correspondence and reprint requests should be ad-289sufficient to direct the release of immature virions, it
appears likely that host factors might be involved in the
folding of the structural polyproteins, the assembly pro-
cess, and viral maturation.
Using a yeast two-hybrid screen to detect cellular
proteins as binding partners for Gag, it was discovered
that the peptidyl prolyl cis–trans isomerase Cyclophilin A
(Cyp A) is an integral constituent of the HIV-1 virion
(Franke et al., 1994; Luban et al., 1993; Thali et al., 1994).
However, it soon became apparent that Cyp A is only
packaged by HIV-1, but not by HIV-2 and simian immu-
nodeficiency virus (SIV) (Billich et al., 1995; Franke et al.,
1994; Thali et al., 1994). Packaging of Cyp A by HIV-1
occurs at a molar ratio of 1:10 (Cyp A:Gag) and is medi-
ated by the N-terminal part of the CA domain of Gag
(Franke et al., 1994). Mutational analysis and structural
studies revealed that Cyp A binds to an exposed loop
comprising amino acids 85–99 of the CA domain and
specifically interacts with Gly89 and Pro90 of CA (Gam-
ble et al., 1996; Gitti et al., 1996; Momany et al., 1996).
Since Cyp A also binds to completely processed CA, it
seems likely that it remains attached to the cone-shaped
capsid after maturation. Incorporation of Cyp A into virus
particles is blocked by the immunosuppressive drug
cyclosporin A (CSA) and CSA treatment results in aoutside the Cyp-binding loop and may aid in determination
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al., 1994), while it has no effect on HIV-2 or SIV. A similar
reduction in infectivity was observed for viruses contain-
ing amino acid substitutions in the Cyp binding loop of
CA, especially when the residues Gly89 and Pro90 were
exchanged (Braaten et al., 1996a; Wiegers et al., 1999). It
was also observed that mutations in the Cyp-binding
loop can confer resistance to CSA treatment, providing
additional genetic evidence that HIV-1 CA is the func-
tional target of Cyp A (Aberham et al., 1996). Furthermore,
SIV could be altered to package Cyp A and to become
sensitive to CSA when either an entire CA domain or an
eight amino acid sequence corresponding to the Cyp A
binding site was replaced by the analogous region of
HIV-1. Using these chimeric viruses, it was shown that
adjacent residues outside the primary binding site influ-
ence the sensitivity or dependence of viral infectivity in
the presence of Cyp A (Braaten et al., 1997; Bukovsky et
al., 1997).
From analysis of CSA-treated and mutant viruses, it
was shown that packaging of Cyp A into HIV-1 virions is
not required for virus release or maturation but appears
to be needed at an early step in the virus life cycle
(Braaten et al., 1996a). According to the prevailing hy-
pothesis, which is mainly based on structural studies
(Gamble et al., 1996), Cyp A-binding to CA would have a
destabilizing effect on the association of CA multimers,
thereby promoting the disassembly of the viral capsid
early in infection (Braaten et al., 1996a; Gamble et al.,
1996). However, comparing Cyp A-binding mutants and
wt virus grown in the presence or absence of CSA did
not reveal a significant effect of Cyp A on virion matura-
tion or capsid stability, and similar results were obtained
when Cyp A was used in in vitro assembly and disas-
sembly experiments (Gra¨ttinger et al., 1999; Wiegers et
al., 1999). Based on these results, it was suggested that
Cyp A does not function to destabilize the viral capsid,
but rather acts as a chaperone during capsid maturation.
Recent studies have implicated a role for Cyp A in the
initial binding of HIV-1 to target cells, arguing that Cyp A
is partially extruded through the viral membrane (Saphire
et al., 1999, 2000; Sherry et al., 1998), but it is difficult to
reconcile this hypothesis with the published results on
Cyp A dependence and resistance.
A particularly intriguing phenotype was observed for
two HIV-1 isolates, belonging to the outlier (O) group of
HIV-1. Group O viruses have been grouped according to
their high-sequence divergence from group M viruses
and are believed to have resulted from an independent
cross-species transmission (Charneau et al., 1994). The
group O viruses analyzed incorporated Cyp A similar to
other HIV-1 strains, but their infectivity was not depen-
dent on Cyp A (Braaten et al., 1996b). Thus, different HIV
groups appeared to be distinguishable by their Cyp A
phenotype: HIV-1 (M) incorporates Cyp A and needs it,
HIV-2 and SIV lack Cyp A and do not need it, and HIV-1
(O) incorporates Cyp A, but does not need it. However, in
our preliminary analysis of group O isolates, we ob-
served differences in their Cyp A dependence. We there-
fore performed a detailed study of Cyp A incorporation
and Cyp A dependence of infectivity for five primary
HIV-1 group O viruses. Here, we report that all viruses
incorporated Cyp A in a CSA-sensitive way, while viral
infectivity was severely affected by CSA treatment in only
three cases and the other two viruses were unaffected.
The different phenotypes could not be correlated with
obvious differences in the Cyp-binding region, indicating
that other regions of CA may also influence the Cyp A
effect.
RESULTS
Previously, it had been shown that packaging of Cyp A
into HIV-1 group M virions is important for viral infectivity
(Braaten et al., 1996a,b; Bukovsky et al., 1997; Franke et
al., 1994; Thali et al., 1994), while group O isolates pack-
aged Cyp A, but appeared to be unaffected by CSA
treatment (Braaten et al., 1996b). In our analysis of two
group O isolates, we observed a differential dependence
on Cyp A for infectivity and we therefore extended this
study to five primary group O isolates, including isolate
MVP 5180 for which the original observation of Cyp A
independence and the sequence of the Cyp loop had
been published (Braaten et al., 1996b). The group O
isolates MVP5180, MVP13470, MVP2901, MVP9435, and
MVP 8913 were obtained from L. Gu¨rtler (Institute of
Medical Virology, University of Greifswald, D-17487
Greifswald, Germany) and have been characterized pre-
viously regarding their coreceptor usage (Dittmar et al.,
1999).
All isolates used in this study were propagated in
PM-1 cells, which had an intermediate Cyp A content
when analyzed in parallel with cell lines H9, Jurkat,
C8166, and MT-4 in a semiquantitative Western blot (data
not shown). To obtain high yields of virus particles, cells
were infected by cocultivation. Six hours after infection,
cultures were split into equal portions and grown for
another 36 h in the absence or presence of CSA (10
g/ml), respectively. Subsequently, cells and superna-
tants were harvested and analyzed by SDS–PAGE and
immunoblotting.
Figure 1A shows the analysis of lysates from untreated
and CSA-treated cells infected with the different isolates.
NL 4-3-infected PM-1 cells were included as control
representative of HIV-1 M-group virus. Completely pro-
cessed CA was detected as the major product in un-
treated and CSA-treated cells. Thus, CSA treatment did
not result in delayed processing of the Gag polyproteins
in any of the isolates. For the analysis of virus particles,
the supernatants from infected cell cultures were pel-
leted through a sucrose cushion. The pellets were re-
suspended in SDS loading buffer and analyzed by SDS–
PAGE and immunoblotting. The results are shown in Fig.
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1B. For better comparison of Cyp A incorporation of the
different isolates, 100 ng p24 as determined by quanti-
tative ELISA was loaded in each lane. Serial dilutions of
NL 4-3 virus grown in the absence of CSA (lanes 13–16)
and serial dilutions of purified Cyp A (lanes 17–19) were
loaded in parallel. Apparently all group O virus isolates
incorporated Cyp A in similar amounts as compared to
NL 4-3. The Cyp A content was roughly 1/10 of the
amount of CA in all cases, as described for HIV-1 group
M viruses. Slight differences in the apparent Cyp content
of the isolates were not reproducible in further experi-
ments. Importantly, cultivation of cells infected with the
different isolates in the presence of CSA blocked Cyp A
incorporation in all isolates (Fig. 1B, lanes ).
The infectivity of HIV-1 M-group isolates requires in-
corporation of Cyp A and it has been shown that CSA
treatment as well as mutations in the Cyp binding loop
reduce infectivity (Braaten et al., 1996a; Bukovsky et al.,
1997; Franke et al., 1994; Thali et al., 1994). In contrast,
infectivity of the group O isolate MVP 5180 did not de-
pend on the presence of Cyp A (Braaten et al., 1996b). We
determined the infectivities of the five different group O
viruses and of NL 4-3 grown in the presence or absence
of CSA. Virus preparations used for infectivity studies
were derived from the same samples that had been
analyzed for their Cyp A content. Viruses were tested in
single-round infectivity assays on HeLa P4/CCR5 indica-
tor cells. The results of two different experiments are
shown in Fig. 2. Three of the five group O isolates (MVP
13470, 2901, and 8913) showed a 70–90% reduction in
infectivity when they were grown in the presence of CSA
and devoid of Cyp A, as illustrated in Fig. 1B. This was
similar to the phenotype observed for the M-group iso-
late NL 4-3. The other two isolates (MVP 5180 and 9435)
did not show a reduction in virus titer, when grown in the
presence of CSA. Instead, a slight increase in titer was
reproducibly observed for MVP 5180, which was previ-
ously shown to be independent of Cyp A. Thus, different
O-group isolates exhibit different dependence on Cyp A
incorporation, although all isolates incorporate Cyp A in
a CSA-sensitive manner.
To elucidate the reason for the differences in Cyp A
dependence, we amplified and sequenced the coding
sequence for the Cyp-binding region of the different
isolates. An alignment of the predicted amino acid se-
quences in comparison with the NL 4-3 sequence and a
consensus sequence for HIV-1 group O (Hackett et al.,
1997) is shown in Fig. 3. Consistent with the finding that
all isolates incorporated normal levels of Cyp A, the
proline-rich region P-X4-P-X2-P-X5-P, which has been
FIG. 2. Infectivity of HIV-1 group O isolates. Cell-free tissue culture
media containing the different group O isolates or NL 4-3 grown for
36 h in the absence () or presence of CSA () were titrated on HeLa
P4/CCR5 indicator cells. All titrations were done in duplicate and mean
values are shown. Ranges of duplicates are indicated by vertical bars.
Light and shadowed columns correspond to two independent experi-
ments using independently prepared virus stocks. Mean titers obtained
from virus grown in the absence of CSA were set to 100% in all cases.
FIG. 1. Immunoblot analysis of HIV-1 Gag proteins and of Cyp A.
PM-1 cells were infected with HIV-1 NL 4-3 and with the different group
O isolates as indicated above each lane. Cells were grown for 36 h in
the absence () or presence () of CSA (10 g/ml), respectively.
Lysates of infected cells (A) or viral particles collected by centrifugation
through a sucrose cushion (B) were analyzed by SDS–PAGE and
Western blotting. Specific products were detected using a polyclonal
antiserum against HIV-1 CA (A) or a mixture of this antiserum and a
polyclonal antiserum against Cyp A (B). In (B), the amount loaded was
normalized according to the HIV-1 CA content (100 ng/lane). Lanes
13–16 correspond to serially diluted NL 4-3 virus grown in the absence
of CSA; lanes 17–19 correspond to 20, 10, and 5 ng Cyp A, respectively.
Molecular mass standards (kDa) are indicated on the left.
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shown to be responsible for Cyp A incorporation, was
found to be conserved in all O-group isolates. Further-
more, the glycine residue in position 89, which is known
to be important for Cyp A packaging, is also conserved in
the O-group isolates. However, all five O-group isolates
differ in position 88 from the NL 4-3 sequence and in four
of them histidine 87 is substituted by an alanine. The
isolate MVP 9435, which is independent of Cyp A incor-
poration, displays a nonconservative substitution in po-
sition 86 (valine to glutamine). Three of the O-group
isolates have additional substitutions immediately down-
stream the Cyp binding loop, i.e., in position 96 (MVP
13470 and MVP 2901) and in position 98 (MVP 8913).
Furthermore, all O-group isolates showed some se-
quence diversity in the region of helix 6 of CA and in
positions C-terminal of this helix.
DISCUSSION
Assembly, maturation, and disassembly of HIV is a
complex process. In the producing cell a stable structure
consisting mostly of Gag polyproteins is assembled. In
an extracellular maturation step this structure is con-
verted into a metastable structure, ready to disassemble
after fusion of the viral membrane with the plasma mem-
brane of the newly infected cell, thereby releasing the
viral genome and replication proteins. Host cell proteins
may be involved in these processes besides the viral
structural proteins, and experiments using the immuno-
suppressive drug CSA as well as mutational analysis
have shown that incorporation of Cyp A is important for
HIV-1 infectivity. The majority of the available data sug-
gests that Cyp A is needed in the early phase of infec-
tion, i.e., after entry and before reverse transcription
(Braaten et al., 1996a). Based on structural analysis, it
had been suggested that binding of Cyp A destabilizes
the mature capsid, thus acting as an uncoating factor in
the newly infected cell (Braaten et al., 1996a; Gamble et
al., 1996). Consequently, it was proposed that viruses
lacking Cyp A would contain more stable capsids unable
to efficiently release the viral genome and the replication
proteins. Our recently published data suggested that Cyp
A more likely exerts its effect by facilitating the coordi-
nated rearrangement of CA subunits during the matura-
tion process (Gra¨ttinger et al., 1999; Wiegers et al., 1999).
However, the exact function of Cyp A in HIV-1 replication
has not been determined to date.
As mentioned before, the related immunodeficiency
viruses HIV-2 and SIV do not package Cyp A nor do they
depend on its presence for replication. However, SIV
could be made to package Cyp A and to depend on its
incorporation when an eight amino acid stretch of the CA
domain was replaced by the analogous region of HIV-1
(Bukovsky et al., 1997). It was therefore speculated that
these viruses use another mechanism which mimics the
effect of Cyp A on HIV-1 CA. The finding that both Cyp
incorporation and Cyp dependence were transferred by
exchange of the Cyp loop argues that this mechanism is
entirely determined by the Cyp loop. This view was
supported by the observation that CSA-resistant variants
of HIV-1 can be selected, which also mapped to the
Cyp-loop (Aberham et al., 1996). Furthermore, it was
shown that Cyp-binding mutants which are unable to
replicate in cells with low Cyp A content can be rescued
in host cells with a higher Cyp A content (Ackerson et al.,
1998). This indicates that a certain stoichiometry of CA
and Cyp A molecules in the virion is optimal for HIV-1
infectivity. In view of these results, the phenotype of
HIV-1 O-group viruses which incorporate Cyp A, but do
not need it for infectivity (Braaten et al., 1996b), is of
particular interest, because it may aid our understanding
FIG. 3. Amino acid sequence alignment of the CA region containing the Cyp-binding loop (numbering is with respect to the amino terminus of the
majority of clade B HIV-1 CA sequences). At the top of the figure, the NL 4-3 sequence and a group O consensus sequence (Hackett et al., 1997) are
shown as indicated. Residues differing from the NL 4-3 sequence are underlined in the group O consensus sequence. In the group O sequences only
mismatches from the O consensus sequence are shown. A dot is used when residues could not be identified. Residues glycine 89 and proline 90,
corresponding to the Cyp A contact site, are boxed. The Cyp A binding loop is indicated by a horizontal bar above the sequence.
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of the role of Cyp A in viral replication. The results of the
present study clearly show, however, that Cyp A inde-
pendence is not a general feature of all group O viruses
with some isolates being inhibited by CSA, similar to
M-type viruses, while others remained completely unaf-
fected. This result also argues against Cyp A being
involved in target-cell binding as recently proposed
(Saphire et al., 1999, 2000; Sherry et al., 1998), because it
is difficult to imagine that closely related group O viruses
with similar Cyp A content use completely different
mechanisms for target cell interaction.
All group O viruses analyzed exhibited Cyp A incorpo-
ration at a level similar to previously studied M-group
viruses, and Cyp A incorporation was always CSA-sen-
sitive. Therefore sequence analysis of the different vari-
ants may allow us to distinguish between amino acid
differences which correlate with the different pheno-
types. Structural and mutational studies had implicated
Pro 90 and Gly 89 as essential residues for Cyp A
binding and these residues were conserved in all group
O isolates, consistent with their incorporation of Cyp A.
However HIV-2 also contains the Gly-Pro dipeptide in the
Cyp-loop and therefore additional residues must play a
role as well. Ala 88, immediately adjacent to the Gly-Pro
dipeptide, is also buried within the Cyp A active site
pocket in the CA–Cyp A cocrystal and has been sug-
gested to be part of the binding determinant. However,
as indicated in Fig. 3, Ala88 is replaced by Met, Val, or Ile
residues in the group O isolates. Furthermore, in vitro
binding studies revealed a much more pronounced de-
crease in Cyp binding, when the Ala88 was exchanged
by Gly instead of Val (Yoo et al., 1997). Thus, hydropho-
bicity, not small size, may be primarily selected for in this
case. His87, which had been suggested to be an addi-
tional determinant for Cyp A-binding specificity, is also
not present in the group O isolates. Instead, a proline is
found in this position in the group O consensus se-
quence and in isolate MVP 2901, while the other isolates
contain an Ala residue at this position. Exchanging His87
to Ala in the NL 4-3 sequence, on the other hand, led to
a marked reduction in the Cyp-binding affinity. Quite
clearly, the Cyp A–CA interface is significantly altered in
the case of group O viruses, while the Cyp A–CA stoi-
chiometry in the virion appears unchanged. Thus, other
regions within the Cyp loop of group O viruses and
beyond may be needed to compensate for the described
changes in the contact site and may effectively increase
the binding energy as previously suggested (Yoo et al.,
1997). However, no obvious candidates for such changes
could be identified in the sequence of the five group O
isolates.
All group O viruses incorporated Cyp A, but two of
them were completely insensitive to CSA treatment,
while the other three exhibited reduced infectivity similar
to M-group viruses. Based on previous results, one may
predict that the different phenotypes are due to differ-
ences in the Cyp-loop sequence. However, no consistent
differences were observed when the sequences of iso-
lates 2901, 8913, and 13470 (Cyp-dependent) were com-
pared with the Cyp-independent isolates 5180 and 9435.
This becomes even more striking when the sequences of
isolates 5180 and 13470 are compared, which are com-
pletely identical in the region from CA AA 53 to 115
except for a conservative Ile to Leu difference at residue
95. Additional differences between these isolates were
observed in helix 6 and in the loop between helix 6 and
helix 7. Whether these residues can modulate the Cyp A
phenotype remains to be determined. Our results indi-
cate that residues outside the primary Cyp A-binding site
may contribute to the Cyp A phenotype. The closely
homologous group O viruses exhibiting different Cyp A
phenotypes which have been described in this report will
be valuable tools for the analysis of Cyp A function in the
future and can be used for the construction of chimeric




The PM-1 cell line was maintained in RPMI 1640 sup-
plemented with 10% heat-inactivated fetal calf serum, 100
U penicillin per ml, 100 g streptomycin per ml, and 2
mM glutamine. HeLa P4 cells (Clavel and Charneau,
1994) stably expressing the CCR5 coreceptor (HeLa P4/
CCR5) were maintained in Dulbecco’s modified minimal
Eagle’s medium supplemented as above.
For single-cycle infectivity assays, HeLa P4/CCR5
cells were plated in 24-well plates and infected in dupli-
cates 1 day after plating with 0.25 ml of serially diluted
virus. Complete medium was added after 2 h. Cells
were cultured for 3 days and fixed and stained with
5-bromo-4-chloro-3-indolyl-galactopyranoside (X-gal) as
described (Kimpton and Emerman, 1992). Blue cells were
counted under the microscope; the mean values were
calculated and multiplied by the virus dilution.
The HIV-1 O group primary isolates MVP 2901,
MVP5180, MVP 8913, MVP 9435, and MVP 13470 were
kindly provided by L. Gu¨rtler (Institute of Medical Virol-
ogy, University of Greifswald, D-17487 Greifswald, Ger-
many). All isolates were cultured and expanded on pri-
mary PMBC and virus stocks were stored in liquid nitro-
gen. For the purpose of this study, the isolates were
passaged in the PM-1 cell line. Infection was done by
cocultivation of fresh PM-1 cells with cells infected with
the different isolates or with the NL 4-3 strain. After 6 h
the cultures were split and cyclosporin A (10 g/ml) was
added to one half of the cultures. Cells and supernatants
were harvested 36 h after infection.
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Purification of virus particles
Extracellular particles were collected from cleared me-
dia (10 min at 400 g followed by filtration through a
0.45-m-pore-size filter) and subsequent centrifugation
through a 2 ml cushion of 20% (w/w) sucrose in PBS at
130.000 g for 90 min at 4°C. Pellets were resuspended in
SDS loading buffer and analyzed by gel electrophoresis
and Western blotting.
Analysis of expression products
HIV antigens were analyzed using a quantitative
ELISA detecting the viral CA protein (Konvalinka et al.,
1995). For protein analysis, cell or particle extracts were
separated on 12.5% SDS–polyacrylamide gels. For immu-
noblot analysis, proteins were transferred to nitrocellu-
lose membranes (Schleicher & Schuell) by electroblot-
ting. Membranes were reacted with rabbit polyclonal
antiserum against HIV-1 CA or Cyp A. Bound antibodies
were detected with peroxidase-conjugated anti-rabbit
serum (Jackson Immunochemicals Inc.). Immune com-
plexes were visualized using enhanced chemilumines-
cence (ECL system; Amersham) according to the manu-
facturers instructions.
Polyclonal rabbit antiserum against HIV-1 CA has been
described previously (Mergener et al., 1992) and anti-
serum against Cyp A was a gift of U. v. Schwedler
(University of Utah).
PCR amplification and sequencing
Genomic DNA was isolated from infected cells using
the DNazol Reagent (Life Technologies). The p24gag re-
gion was amplified by polymerase chain reaction (PCR).
For the isolates MVP 13470, 2901, 5180, and 8913 the
following primer pair was used: (5AATACTGCTGTG-
TATCCTCC 3) and (5TTCTATAGATGTCTCCTACTG 3),
corresponding to nucleotides 1133–1152 and 1628–1608
of the HIV-1ANT70 sequence (Vanden Haesevelde et al.,
1994). This primer pair did not give a product for the
isolate MVP 9435 and the following different primer pair
had to be used: (5GCTACAGCAGTTAGAGCCAGCTCT-
CAAGAC 3) and (5CTATCCATTTTCTATAGATGTCTC-
CTACTG 3), corresponding to nucleotides 1021–1050
and 1608–1638 of HIV-1ANT70. Amplification products
were purified with the QIAquick PCR purification kit (Qia-
gen) and sequenced directly on an automated DNA se-
quencer (ABI 100 Model 377, Perkin–Elmer).
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